Clinical Trial Update: Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 adaptive platform trial Horizon Two for high-risk newly diagnosed multiple myeloma is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Multiple Myeloma Research Consortium | Conditions: High Risk Newly Diagnosed Multiple Myeloma | Phase 2 | Status: NOT_YET_RECRUITING